Share
Other content recommended for you
- The unethical use of ethical rhetoric: the case of flibanserin and pharmacologisation of female sexual desire
- Drug flibanserin–in hypoactive sexual desire disorder
- Bremelanotide and flibanserin for low sexual desire in women: the fallacy of regulatory precedent
- Merging of marketing and medical science: female sexual dysfunction
- What are the prevalence and factors associated with sexual dysfunction in breastfeeding women? A Brazilian cross-sectional analytical study
- Evening the score on sex drugs: feminist movement or marketing masquerade?
- Evidence & Ethics: Once More into the Fray
- The marketing of a disease: female sexual dysfunction
- US drug agency approves drug for low sexual desire in women
- What factors are associated with reporting lacking interest in sex and how do these vary by gender? Findings from the third British national survey of sexual attitudes and lifestyles